Latest Alzheimer's disease Stories

BRENTWOOD, Tenn., May 23, 2013 /PRNewswire/ -- Brookdale concluded a record-breaking fundraising season benefitting the Alzheimer's Association. The nation's largest operator of senior living communities raised more than $750,000 - well beyond its goal as a Platinum National Team for the Walk to End Alzheimer's(®) 2012 fundraising season, a 50 percent increase over the more than $500,000 the company raised in 2011. In 2010, Brookdale collected nearly $500,000, bringing the company's...

Novel drug treatment facilitates recovery of memory, mood and cognitive function. The improved self-suficiency enables a lower level of care according to a recent NWC observational study. (PRWEB) May 22, 2013 Neurological Recovery Guide and Neurological Wellness Center have been facilitating recovery from Alzheimer's disease since 2010.This breakthrough therapy results in rapid cognitive improvement by reducing inflammation in the brain. A growing body of published research has linked...

GeriJoy provides virtual talking dogs as companions for the elderly. Following anecdotal evidence of GeriJoy's senior companionship service improving mental health and even rolling back Alzheimer's, Pace University will begin a research study this summer to determine the clinical efficacy of the GeriJoy Companion system. New York, NY (PRWEB) May 22, 2013 Research shows that loneliness is a significant risk factor for Alzheimer's, other functional decline, and even death in...

Funds to Advance Research Across Key Tau Programs in Alzheimer's disease NEW YORK, May 22, 2013 /PRNewswire/ -- Oligomerix, Inc., a privately held company pioneering the development of disease modifying therapeutics for Alzheimer's disease (AD) and related neurodegenerative disorders, announced today the completion of its Series B financing, which includes both issuance of new convertible preferred shares and warrants that would represent approximately $2.8M in new investments in...

Football in Cleveland to Get a Whole New Look for an Important Cause CLEVELAND, May 22, 2013 /PRNewswire/ -- This football town is about to change its colors...at least for one day. Blondes vs. Brunettes, a women's flag football game, is coming to Cleveland Saturday, June 15 to support the Alzheimer's Association Cleveland Area Chapter. The public is invited to help in the fight against Alzheimer's disease by coming out to cheer on their favorite team - blonde or brunette!...

This book is the culmination of over 50 years of experience with the world of dementia. The book’s six sections explore topics basic to caregivers developing their own techniques and approaches to managing the day-to-day care of their loved ones. Albuquerque, New Mexico (PRWEB) May 21, 2013 Barbara Michels, author of “The Alzheimer’s Journey…A Practical Perspective for Caregivers” has over 50 years of experience in the world of dementia. Over 25 years was the process of losing...

Journal of Huntington's Disease studies examine options While Huntington's disease (HD) is currently incurable, the HD research community anticipates that new disease-modifying therapies in development may slow or minimize disease progression. The success of HD research depends upon the identification of reliable and sensitive biomarkers to track disease and evaluate therapies, and these biomarkers may eventually be used as outcome measures in clinical trials. Biomarkers could be...

King presents her arduous journey, plus insightful advice on how to tackle A.D. MAITLAND, Fla., May 21, 2013 /PRNewswire-iReach/ -- In her new book, STOLEN: A DAUGHTER'S CHRONOLOGY OF ALZHEIMER'S DISEASE AND THE IMPACT OF IN-HOME-CARE ($16.49, paperback, 978-1-62509-933-4; $26.49, hardcover, 978-1-62509-934-1; $8.99, e-book, 978-1-62509-935-8) Lora D. King outlines the grim facts and statistics about Alzheimer's disease. Furthermore, she shares first-hand experience as the primary...

Clinical Data on CERE-120 (AAV-NRTN) Presented at the 16th Annual Meeting of the American Society of Gene and Cellular Therapy (ASGCT) SAN DIEGO, May 21, 2013 /PRNewswire/ -- Ceregene, Inc. today announced additional efficacy data from a secondary analysis of its double-blind, randomized, controlled Phase 2b clinical study of CERE-120 (AAV-neurturin). CERE-120 is a gene therapy product designed to deliver the neurotrophic factor neurturin, for Parkinson's disease. This exploratory...

Resources available to help family caregivers determine their risk and minimize negative health effects before they escalate OMAHA, Neb., May 20, 2013 /PRNewswire/ -- The Home Instead Senior Care(® )network, the leading global provider of in-home non-medical care services for seniors, today announced the release of two new resources that aim to help family caregivers determine their risk for caregiver distress, and to minimize key health effects that are associated with...